HIV Drugs
Dolutegravir, lamivudine, tenofovir-DF (TLD) has been added to the interaction checker as a new antiretroviral combination. TLD is formulated as a fixed-dose combination tablet and is one of the fixed-dose ARV combinations on the WHO Essential Medicines list. TLD is only available in low or middle-income countries or in some high-income countries where there are a high percentage of HIV positive people. TLD is not available in Europe, the UK or the US as dolutegravir is still under patent in most high-income countries.
Co-medications
Selegiline (Parkinsonism Agents) and tobramycin (Antibacterials) have been added to the list of co-medications.
